{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:00:17Z","timestamp":1792724417032,"version":"4.5.0"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T00:00:00Z","timestamp":1734998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"NHMRC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Gedeon-Richter and Vianex"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>STUDY QUESTION<\/jats:title>\n                  <jats:p>Is the probability of pregnancy different between women using biosimilars versus the originator of follitropin alfa for ovarian stimulation in ART?<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>SUMMARY ANSWER<\/jats:title>\n                  <jats:p>Meta-analysis of eight randomized clinical trials (RCTs) suggests that live birth, clinical, and ongoing pregnancy rates are significantly lower with biosimilars of follitropin alfa compared to the originator.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>WHAT IS KNOWN ALREADY<\/jats:title>\n                  <jats:p>All biosimilars of follitropin alfa have received regulatory approval by demonstrating non-inferiority in the number of retrieved oocytes compared to the originator. Nevertheless, the most clinically relevant outcome in ART for both clinicians and patients is live birth. A meta-analysis published in 2021 suggested that biosimilars of follitropin alfa are associated with lower live birth rates compared to the originator. Since then, more relevant RCTs have been published, and thus an updated critical synthesis of the available evidence is urgently warranted.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>STUDY DESIGN, SIZE, DURATION<\/jats:title>\n                  <jats:p>A systematic review and meta-analysis were performed to compare biosimilars versus the originator of follitropin alfa in women undergoing ovarian stimulation for ART. A literature search was conducted until January 2024 in MEDLINE, Embase, Cochrane CENTRAL, Scopus, Web of Science, WHO, Clinicaltrials.gov, and others to identify eligible RCTs. The primary outcome was live birth. Secondary outcomes included clinical and ongoing pregnancy, duration of gonadotrophin administration and total FSH dose, number of oocytes retrieved, and ovarian hyperstimulation syndrome (OHSS).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>PARTICIPANTS\/MATERIALS, SETTING, METHODS<\/jats:title>\n                  <jats:p>Data were extracted independently by two reviewers. Quality was assessed using the RoB-2 Tool by Cochrane, and a sensitivity analysis was performed by excluding studies having high risk of bias. Meta-analysis was performed using the random or fixed effects model depending on the presence or not of significant (&amp;gt;50%) statistical heterogeneity (I2). Results were combined using the intention-to-treat principle and are reported as risk ratio (RR) or weighted-mean-difference (WMD) with 95% CIs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>MAIN RESULTS AND THE ROLE OF CHANCE<\/jats:title>\n                  <jats:p>Eight RCTs (n\u2009=\u20092987) (published between 2015 and 2023) were identified, assessing seven biosimilar products of follitropin alfa. The number of patients included in the eligible studies ranged from 100 to 1100. Three of the RCTs were deemed to be at high risk of bias. The duration of gonadotrophin administration was shorter in the biosimilars group (WMD: \u20130.19\u2009days, 95% CI: \u20130.34 to \u20130.05; I2 = 0%, 5 studies, n\u2009=\u20092081), while no difference was observed in the total dose of FSH (WMD: \u201334.69 IUs, 95% CI: \u201374.54 to 5.16; I2 = 15.53%, 5 studies, n\u2009=\u20092081). No difference was observed in the number of oocytes retrieved (WMD: 0.27, 95% CI: \u20130.43 to 0.96; I2 = 10.7%, 6 studies, n\u2009=\u20091527) and OHSS rates (RR: 1.17, 95% CI: 0.90\u20131.52; I2 = 0%, 8 studies, n\u2009=\u20092986) between the two groups. A significantly lower live birth rate was observed using the biosimilars of follitropin alfa compared to the originator in women undergoing ovarian stimulation for ART (RR: 0.83, 95% CI: 0.72\u20130.96; I2 = 0%, 6 studies, n\u2009=\u20092335; moderate certainty of evidence). Similarly, clinical pregnancy (RR: 0.82, 95% CI: 0.73\u20130.92; I2 = 0%, 7 studies, n\u2009=\u20092876; low certainty of evidence) and ongoing pregnancy rates (RR: 0.81, 95% CI: 0.70\u20130.94; I2 = 0%, 7 studies, n\u2009=\u20091886; low certainty of evidence) were lower in the biosimilars group. These results were not materially altered in the sensitivity analyses performed where studies deemed at high risk of bias were excluded.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>LIMITATIONS, REASONS FOR CAUTION<\/jats:title>\n                  <jats:p>This meta-analysis included RCTs evaluating seven different biosimilars of follitropin alfa; however, pooled data appeared to be homogeneous. No data were available comparing biosimilars of follitropin alfa with the originator regarding cumulative live birth rate per aspiration or the probability of live birth in frozen thawed cycles. The population examined in the eligible RCTs includes mainly normal responders and no RCTs were identified focusing on poor or high responders.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>WIDER IMPLICATIONS OF THE FINDINGS<\/jats:title>\n                  <jats:p>Clinicians should be informed that although biosimilars of follitropin alfa produce similar number of oocytes with the originator, pregnancy rates after a fresh transfer are likely to be lower. Future research should focus on optimizing the production and use of biosimilars of follitropin alfa, so that they lead to pregnancy rates comparable to the originator.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>STUDY FUNDING\/COMPETING INTEREST(S)<\/jats:title>\n                  <jats:p>No external funding was used for this study. K.I.K. and A.S. have no competing interest to disclose. E.M.K. reports personal fees and non-financial support from Merck, Ferring, IBSA, and Vianex. B.W.M. has been supported by an investigator grant from NHMRC, has received consulting fees from Organon, Merck, and Norgine, research support and non-financial support from Merck KGaA, Darmstadt, Germany. B.W.M. also reports having stocks from OBsEva. C.A.V. reports grants, personal fees, and non-financial support from Merck KGaA, Darmstadt, Germany, personal fees, and non-financial support from Merck, Sharpe and Dohme, personal fees and non-financial support from Organon, grants and non-financial support from Ferring, personal fees from IBSA, and personal fees and non-financial support from Gedeon Richter and Vianex.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>REGISTRATION NUMBER<\/jats:title>\n                  <jats:p>Protocol for the systematic review registered in The International Prospective Register of Systematic Reviews (PROSPERO; CRD42024498237).<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/humrep\/deae274","type":"journal-article","created":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T20:10:11Z","timestamp":1735071011000},"page":"343-359","source":"Crossref","is-referenced-by-count":11,"title":["Biosimilars versus the originator of follitropin alfa for ovarian stimulation in ART: a systematic review and meta-analysis"],"prefix":"10.1093","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-7546-4659","authenticated-orcid":false,"given":"Kokkoni I","family":"Kiose","sequence":"first","affiliation":[{"name":"Unit for Human Reproduction, 1st Dept of Obstetrics and Gynaecology, Medical School, Faculty of Health Sciences, Aristotle University of Thessaloniki , Thessaloniki,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashleigh","family":"Storr","sequence":"additional","affiliation":[{"name":"Fertility Associates , Auckland,","place":["New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0031-9460","authenticated-orcid":false,"given":"Efstratios M","family":"Kolibianakis","sequence":"additional","affiliation":[{"name":"Unit for Human Reproduction, 1st Dept of Obstetrics and Gynaecology, Medical School, Faculty of Health Sciences, Aristotle University of Thessaloniki , Thessaloniki,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben W","family":"Mol","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, University of Monash , Monash, Clayton, VIC,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9591-7222","authenticated-orcid":false,"given":"Christos A","family":"Venetis","sequence":"additional","affiliation":[{"name":"Unit for Human Reproduction, 1st Dept of Obstetrics and Gynaecology, Medical School, Faculty of Health Sciences, Aristotle University of Thessaloniki , Thessaloniki,","place":["Greece"]},{"name":"Centre for Big Data Research in Health, Faculty of Medicine & Health, University of New South Wales , Sydney, NSW,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,12,24]]},"reference":[{"key":"2025020305513570600_deae274-B1","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ejogrb.2019.07.032","article-title":"A multicenter, randomized, phase III study comparing the efficacy and safety of follitropin alpha biosimilar and the original follitropin alpha","volume":"241","author":"Barakhoeva","year":"2019","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"2025020305513570600_deae274-B2","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1093\/humrep\/deq125","article-title":"Circulating progesterone levels and ongoing pregnancy rates in controlled ovarian stimulation cycles for in vitro fertilization: analysis of over 4000 cycles","volume":"25","author":"Bosch","year":"2010","journal-title":"Hum Reprod"},{"key":"2025020305513570600_deae274-B3","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.fertnstert.2014.03.047","article-title":"Ongoing pregnancy qualifies best as the primary outcome measure of choice in trials in reproductive medicine: an opinion paper","volume":"101","author":"Braakhekke","year":"2014","journal-title":"Fertil Steril"},{"key":"2025020305513570600_deae274-B4","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ejogrb.2018.04.006","article-title":"Treatment strategies and cumulative live birth rates in WHO-II ovulation disorders","volume":"225","author":"Braam","year":"2018","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"2025020305513570600_deae274-B5","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12958-021-00727-y","article-title":"Biosimilar recombinant follitropin alfa preparations versus the reference product (Gonal-F) in couples undergoing assisted reproductive technology treatment: a systematic review and meta-analysis","volume":"19","author":"Chua","year":"2021","journal-title":"Reprod Biol Endocrinol"},{"key":"2025020305513570600_deae274-B6","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/j.fertnstert.2009.11.018","article-title":"Measuring outcomes in fertility trials: can we rely on clinical pregnancy rates?","volume":"94","author":"Clarke","year":"2010","journal-title":"Fertil Steril"},{"key":"2025020305513570600_deae274-B7","doi-asserted-by":"crossref","first-page":"103524","DOI":"10.1016\/j.drudis.2023.103524","article-title":"Randomized controlled trials do not always fit the purpose: a science-based response to Venetis and Mol\u2019s editorial on biosimilars of follitropin alfa","volume":"28","author":"de Mora","year":"2023","journal-title":"Drug Discov Today"},{"key":"2025020305513570600_deae274-B8"},{"key":"2025020305513570600_deae274-B9","doi-asserted-by":"crossref","first-page":"636038","DOI":"10.3389\/fendo.2021.636038","article-title":"New human follitropin preparations: how glycan structural differences may affect biochemical and biological function and clinical effect","volume":"12","author":"Dias","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2025020305513570600_deae274-B10","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"2025020305513570600_deae274-B11","author":"European Medicines Agency","year":"2010"},{"key":"2025020305513570600_deae274-B12","author":"European Medicines Agency","year":"2014"},{"key":"2025020305513570600_deae274-B13","author":"Fertility Biotech AG","year":"2017"},{"key":"2025020305513570600_deae274-B14","author":"Food and Drug Administration","year":"2013"},{"key":"2025020305513570600_deae274-B31","author":"GRADEpro GDT: GRADEpro Guideline Development Tool [Software]. McMaster University and Evidence Prime, 2024. Available from gradepro.org."},{"key":"2025020305513570600_deae274-B15","doi-asserted-by":"crossref","first-page":"102308","DOI":"10.1016\/j.bpobgyn.2022.102308","article-title":"Comparative effectiveness of gonadotropins used for ovarian stimulation during assisted reproductive technologies (ART) in France: a real-world observational study from the French nationwide claims database (SNDS)","volume":"88","author":"Grynberg","year":"2023","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"2025020305513570600_deae274-B16","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1002\/sim.1009","article-title":"A refined method for the meta-analysis of controlled clinical trials with binary outcome","volume":"20","author":"Hartung","year":"2001","journal-title":"Stat Med"},{"key":"2025020305513570600_deae274-B17","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1136\/eb-2013-101494","article-title":"Understanding triangulation in research","volume":"16","author":"Heale","year":"2013","journal-title":"Evid Based Nurs"},{"key":"2025020305513570600_deae274-B18","author":"Higgins","year":"2024"},{"key":"2025020305513570600_deae274-B19","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.rbmo.2022.10.006","article-title":"Comparison of recombinant human FSH biosimilar QL1012 with Gonal-f\u00ae for ovarian stimulation: a phase-three trial","volume":"46","author":"Hu","year":"2023","journal-title":"Reprod Biomed Online"},{"key":"2025020305513570600_deae274-B20","doi-asserted-by":"crossref","first-page":"4918","DOI":"10.18632\/aging.102919","article-title":"Efficacy and safety of recombinant human follicle-stimulating hormone in patients undergoing in vitro fertilization-embryo transfer","volume":"12","author":"Hu","year":"2020","journal-title":"Aging (Albany NY)"},{"key":"2025020305513570600_deae274-B21","first-page":"5951","article-title":"Correction for: Efficacy and safety of recombinant human follicle-stimulating hormone in patients undergoing in vitro fertilization-embryo transfer","volume":"15","author":"Hu","year":"2023","journal-title":"Aging (Albany NY)"},{"key":"2025020305513570600_deae274-B22","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1471-2288-14-25","article-title":"The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method","volume":"14","author":"IntHout","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"2025020305513570600_deae274-B23","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.rbmo.2020.10.008","article-title":"Is there an optimal number of oocytes retrieved at which live birth rates or cumulative live birth rates per aspiration are maximized after ART? A systematic review","volume":"42","author":"Law","year":"2021","journal-title":"Reprod Biomed Online"},{"key":"2025020305513570600_deae274-B24","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1093\/humrep\/dez100","article-title":"The number of oocytes associated with maximum cumulative live birth rates per aspiration depends on female age: a population study of 221 221 treatment cycles","volume":"34","author":"Law","year":"2019","journal-title":"Hum Reprod"},{"key":"2025020305513570600_deae274-B25","doi-asserted-by":"crossref","first-page":"429","DOI":"10.3389\/fendo.2019.00429","article-title":"The development of gonadotropins for clinical use in the treatment of infertility","volume":"10","author":"Lunenfeld","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2025020305513570600_deae274-B26","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1056\/NEJMoa0803072","article-title":"Cumulative live-birth rates after in vitro fertilization","volume":"360","author":"Malizia","year":"2009","journal-title":"N Engl J Med"},{"key":"2025020305513570600_deae274-B27","doi-asserted-by":"crossref","first-page":"6762","DOI":"10.3390\/ijms23126762","article-title":"Comparative assessment of the structural features of originator recombinant human follitropin alfa versus recombinant human follitropin alfa biosimilar preparations approved in non-European regions","volume":"23","author":"Manzi","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2025020305513570600_deae274-B28","doi-asserted-by":"crossref","first-page":"e0184139","DOI":"10.1371\/journal.pone.0184139","article-title":"In-vivo biological activity and glycosylation analysis of a biosimilar recombinant human follicle-stimulating hormone product (Bemfola) compared with its reference medicinal product (GONAL-f)","volume":"12","author":"Mastrangeli","year":"2017","journal-title":"PLoS One"},{"key":"2025020305513570600_deae274-B29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/humrep\/deh028","article-title":"What is the most relevant standard of success in assisted reproduction? The singleton, term gestation, live birth rate per cycle initiated: the BESST endpoint for assisted reproduction","volume":"19","author":"Min","year":"2004","journal-title":"Hum Reprod"},{"key":"2025020305513570600_deae274-B30","first-page":"524","article-title":"Efficacy, safety, and immunogenicity of a biosimilar recombinant human follicle-stimulating hormone (Folitime) vs. gonal-f in women undergoing ovarian stimulation for IVF: a randomized, multicenter, evaluator-blinded, non-inferiority study","volume":"25","author":"Pasqualini","year":"2021","journal-title":"Jornal Brasileiro de Reproducao Assistida"},{"key":"2025020305513570600_deae274-B32","first-page":"1015","article-title":"Comparing a biosimilar follitropin alfa (Cinnal-f) with Gonal-f in women undergoing ovarian stimulation: an RCT","volume":"19","author":"Rashidi","year":"2021","journal-title":"Int J Reprod Biomed"},{"key":"2025020305513570600_deae274-B33","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.rbmo.2015.01.005","article-title":"A multi-centre phase 3 study comparing efficacy and safety of Bemfola versus Gonal-f in women undergoing ovarian stimulation for IVF","volume":"30","author":"Rettenbacher","year":"2015","journal-title":"Reprod Biomed Online"},{"key":"2025020305513570600_deae274-B34","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3389\/fendo.2019.00503","article-title":"Glycosylation pattern and in vitro bioactivity of reference follitropin alfa and biosimilars","volume":"10","author":"Riccetti","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2025020305513570600_deae274-B35","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.bpobgyn.2022.01.011","article-title":"Originator recombinant human follitropin alfa versus recombinant human follitropin alfa biosimilars in Spain: a cost-effectiveness analysis of assisted reproductive technology related to fresh embryo transfers","volume":"85","author":"Schwarze","year":"2022","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"2025020305513570600_deae274-B36","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2025020305513570600_deae274-B37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12958-015-0135-8","article-title":"Randomized, active-controlled, comparative phase 3 efficacy and safety equivalence trial of Ovaleap\u00ae (recombinant human follicle-stimulating hormone) in infertile women using assisted reproduction technology (ART)","volume":"14","author":"Strowitzki","year":"2016","journal-title":"Reprod Biol Endocrinol"},{"key":"2025020305513570600_deae274-B38","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12958-023-01114-5","article-title":"Correction: biosimilar recombinant follitropin alfa preparations versus the reference product (Gonal-F\u00ae) in couples undergoing assisted reproductive technology treatment: a systematic review and meta-analysis","volume":"21","author":"Venetis","year":"2023","journal-title":"Reprod Biol Endocrinol"},{"key":"2025020305513570600_deae274-B39","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/humrep\/deu362","article-title":"Estimating the net effect of progesterone elevation on the day of hCG on live birth rates after IVF: a cohort analysis of 3296 IVF cycles","volume":"30","author":"Venetis","year":"2015","journal-title":"Hum Reprod"},{"key":"2025020305513570600_deae274-B40","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1093\/humrep\/dew141","article-title":"Basal serum progesterone and history of elevated progesterone on the day of hCG administration are significant predictors of late follicular progesterone elevation in GnRH antagonist IVF cycles","volume":"31","author":"Venetis","year":"2016","journal-title":"Hum Reprod"},{"key":"2025020305513570600_deae274-B41","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/humupd\/dmt014","article-title":"Progesterone elevation and probability of pregnancy after IVF: a systematic review and meta-analysis of over 60 000 cycles","volume":"19","author":"Venetis","year":"2013","journal-title":"Hum Reprod Update"},{"key":"2025020305513570600_deae274-B42","doi-asserted-by":"crossref","first-page":"103425","DOI":"10.1016\/j.drudis.2022.103425","article-title":"Biosimilars versus the originator of follitropin alfa: randomized controlled trials are still the best way to evaluate their comparative effectiveness in assisted reproduction","volume":"28","author":"Venetis","year":"2023","journal-title":"Drug Discov Today"},{"key":"2025020305513570600_deae274-B43","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/humrep\/dey342","article-title":"Is more better? A higher oocyte yield is independently associated with more day-3 euploid embryos after ICSI","volume":"34","author":"Venetis","year":"2019","journal-title":"Hum Reprod"},{"key":"2025020305513570600_deae274-B44","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.rbmo.2019.06.013","article-title":"Is there an association between oocyte number and embryo quality? A systematic review and meta-analysis","volume":"39","author":"Vermey","year":"2019","journal-title":"Reprod Biomed Online"},{"key":"2025020305513570600_deae274-B45","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1021\/acs.jproteome.5b00921","article-title":"Comparative assessment of glycosylation of a recombinant human FSH and a highly purified FSH extracted from human urine","volume":"15","author":"Wang","year":"2016","journal-title":"J Proteome Res"},{"key":"2025020305513570600_deae274-B46","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.fertnstert.2017.06.005","article-title":"The International Glossary on Infertility and Fertility Care, 2017","volume":"108","author":"Zegers-Hochschild","year":"2017","journal-title":"Fertil Steril"},{"key":"2025020305513570600_deae274-B47","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.rbmo.2020.11.010","article-title":"Female age is associated with the optimal number of oocytes to maximize fresh live birth rates: an analysis of 256,643 fresh ART cycles","volume":"42","author":"Zhang","year":"2021","journal-title":"Reprod Biomed Online"}],"container-title":["Human Reproduction"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/humrep\/article-pdf\/40\/2\/343\/61272543\/deae274.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/humrep\/article-pdf\/40\/2\/343\/61272543\/deae274.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T05:52:09Z","timestamp":1738561929000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/humrep\/article\/40\/2\/343\/7932211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,24]]},"references-count":47,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,12,24]]},"published-print":{"date-parts":[[2025,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/humrep\/deae274","relation":{},"ISSN":["0268-1161","1460-2350"],"issn-type":[{"value":"0268-1161","type":"print"},{"value":"1460-2350","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2024,12,24]]}}}